Patent Claims

1. A pharmaceutical composition comprising:
(a) nebivolol and/or a pharmaceutically acceptable salt thereof, and
(b) a liquid vehicle comprising a semifluorinated alkane.

2. The pharmaceutical composition according to claim 1, comprising a semifluorinated alkane of the formula (II)

$$CF_3(CF_2)_n(CH_2)_mCH_3 \quad (II),$$

wherein n is an integer from 2 to 10 and m is an integer from 2 to 10;

or

wherein n is an integer from 3 to 5 and m is an integer from 4 to 7

3. The pharmaceutical composition of claim 1 or 2, wherein the semifluorinated alkane is selected from the group consisting of 1-perfluorobutyl-pentane ($CF_3(CF_2)_3(CH_2)_4CH_3$; F4H5) and 1-perfluorohexyl-octane ($CF_3(CF_2)_5(CH_2)_7CH_3$, F6H8).

4. The pharmaceutical composition of any preceding claim, wherein the nebivolol and/or a pharmaceutically acceptable salt thereof is suspended in the liquid vehicle comprising a semifluorinated alkane.

5. The pharmaceutical composition of any preceding claim, wherein nebivolol and/or a pharmaceutically acceptable salt thereof is suspended in the liquid vehicle at a concentration of from 0.3 to 1.5 % (w/v).

6. The pharmaceutical composition of any preceding claim, wherein nebivolol and/or a pharmaceutically acceptable salt thereof is suspended in the liquid vehicle at a concentration of from 0.45 to 1.0 % (w/v).

7. The pharmaceutical composition of any preceding claim, comprising nebivolol in the form of nebivolol hydrochloride.

8. The pharmaceutical composition of any of claim 4 to 7, wherein at least about 90% of the suspended particles of nebivolol and/or a pharmaceutically acceptable salt thereof have a size of not more than about 15 μm.

9. The pharmaceutical composition of any preceding claims for use as a medicament.

10. The pharmaceutical composition of any preceding claim for use in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith.

11. The pharmaceutical composition for use according to claim 10, wherein the composition is administered to the eye of a subject, preferably once daily.

12. The pharmaceutical composition for the use according to any of claims 10 or 11, wherein the pharmaceutical composition is administered in a dose volume per eye of 8 to 15 μl, preferably from about 10 to 12 μl.

13. The pharmaceutical composition for the use according to any of claims 10 to 12, wherein the pharmaceutical composition is administered in a dose volume per eye of 10 to 12 μl and nebivolol and/or a pharmaceutically acceptable salt thereof is suspended in the liquid vehicle in a concentration of at least 0.3 % (w/v).

14. The pharmaceutical composition for the use according to any of claims 10 to 13, wherein nebivolol and/or a pharmaceutically acceptable salt thereof is suspended in the liquid vehicle in a concentration of from 0.45 to 1.0 % (w/v).

15. A kit comprising the pharmaceutical composition according to any of the preceding claims and a container for holding the pharmaceutical composition.